Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Rallybio Corp
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Under the Sanofi License Agreement, Sanofi provides Rallybio IPE with worldwide exclusive rights to Sanofi's KY1066, which is now referred to as RLYB331.”
FILING10-K0001628280-26-018261cik 0001739410
“We acquired all rights to RLYB116 and RLYB114 from Sobi in 2019.”
FILING10-K0001628280-26-018261cik 0001739410
“We acquired rights to RLYB116 from Swedish Orphan Biovitrum AB (Publ) ("Sobi").”
FILING10-K0001628280-26-018261cik 0001739410
“Pursuant to the J&J Collaboration Agreement, we received an upfront payment of $0.5 million from J&J for the information dissemination and data provision services under the agreement.”
FILING10-K0001628280-26-018261cik 0001739410
“In July 2025, we entered into a Membership Interest Purchase Agreement (the "ENPP1 Purchase Agreement") with Recursion Exscientia Ventures I, Inc., an indirect wholly-owned subsidiary of Recursion ("Buyer") and Rallybio IPB, LLC, a wholly-owned subsidiary of Rallybio Corporation to sell our interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with HPP, to Buyer (a subsidiary of our joint venture partner Recursion) (the "JV Sale").”
FILING10-K0001628280-26-018261cik 0001739410
“We are obligated to make certain payments under our agreements with Affibody, Sobi, and Kymab Limited ("Sanofi"), including milestone and royalty payments in connection with achievement of certain development and commercial milestones as well as the sale of resulting products under such agreements.”
FILING10-K0001628280-26-018261cik 0001739410
“Pursuant to the PLA, we obtained a license to the Affibody platform technology and a particular ABD, in order to further develop and commercialize certain Affibody ligands, which we are now developing as RLYB116 and RLYB114.”
FILING10-K0001628280-26-018261cik 0001739410
“Under the Sales Agreement, TD Cowen will be entitled to compensation equal to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement.”
FILING10-K0001628280-26-018261cik 0001739410
“The collaboration was designed to allow Rallybio to add product candidates to its existing pipeline and provide the option for AbCellera to conduct process development and clinical manufacturing activities.”
FILING10-K0001628280-26-018261cik 0001739410
Watchlist prices, news filtered to it, and its next report on your desk.
Rallybio Corp has 7 disclosed suppliers and 2 disclosed customers. Each one is named in an SEC filing, either Rallybio Corp’s own annual report or the counterparty’s, and carries the sentence that discloses it.
RLYB (Rallybio Corp) has 7 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: SNY +0.12%, in industrials & materials.